P&G Health appoints Shine Matthew Sunny, reshuffles senior management

Procter & Gamble Health Limited has restructured its senior management team to strengthen its commercial and sales leadership, effective July 1, 2026. The company announced the appointment of Shine Matthew Sunny as the new Marketing Strategy and Planning leader, Commercial Excellence & E-commerce Leader, while three existing senior executives have been reassigned to different regional and functional roles.

The reshuffle involves internal organizational changes where Mr. Abhijit Roy, Mr. M. Padmakar Rao, and Mr. Nilesh Barbade will transition to new designations. These adjustments aim to leverage the extensive experience of the leadership team across sales, trade, and institutional business verticals.

Changes in Senior Management Personnel

The following table details the new roles effective July 1, 2026:

Name	Designation as on date	Designation effective July 1	Nature of Change
Mr. Abhijit Roy	Marketing Strategy and Planning leader, E-commerce & Commercial Excellence Leader	Sales Leader (South and East region) and Exports Leader	Role-change
Mr. M. Padmakar Rao	Sales Leader (West and South region)	Sales Leader (North & West region) and Institutional Business Leader	Role-change
Mr. Nilesh Barbade	Sales Leader (North and East region)	Sales Leader (Trade)	Role-change
Mr. Shine Matthew Sunny	-	Marketing Strategy and Planning leader, Commercial Excellence & E-commerce Leader	Appointment

Executive Profiles

Mr. Abhijit Roy brings over 30 years of experience in the Pharma/OTC sector, including 22 years at Merck India. A science graduate from Guwahati University, he has held various sales leadership roles and currently serves as Director of Sales at P&G Health.

Mr. M. Padmakar Rao holds a B.Sc. from Osmania University and a Post Graduate Diploma in Pharmaceutical Business Management. With over 25 years in the pharmaceutical industry, his expertise spans field sales, marketing operations, and trade channel management.

Mr. Nilesh Barbade possesses an MBA from UAS, Dharwad, and a B.Sc. degree. He has over 26 years of experience in the pharmaceutical industry, including leadership roles in sales, institutional business, and distributor operations.

Mr. Shine Matthew Sunny, the new appointee, has a Post-graduate Diploma in Management from IMIS, Bhubaneswar, and a B.Com degree from St. Xavier's College. He brings over 15 years of experience from P&G and Reckitt Benckiser, specializing in sales strategy, commercial excellence, and e-commerce.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.25%	+7.86%	+10.01%	+27.17%	+17.78%	+19.45%

Procter & Gamble Health Limited has recommended a final dividend of Rs 45 per equity share for the financial year 2025-26, subject to shareholder approval at the ensuing Annual General Meeting. The dividend applies to shares with a face value of Rs 10 each and will be paid to shareholders whose names appear in the Register of Members or depository records as on the record date. The company has detailed the tax deduction at source (TDS) implications, noting that dividend income is taxable in the hands of shareholders under the Income Tax Act, 1961, and the Finance Act, 2020.

Tax Deduction Rates for Resident Shareholders

The company will withhold tax on dividend income paid to resident shareholders as per Section 194 of the Income Tax Act. The applicable TDS rates depend on the total dividend amount and the documentation provided by the shareholder.

Particulars of resident shareholders	Applicable rate	Documents required, if any
Total dividend does not exceed INR 10,000	Nil	-
Valid Form 121 is furnished	Nil	Duly signed Form 121
PAN is available	10%	PAN updated with depositories or RTA
PAN is not available/invalid PAN	20%	-
LIC, GIC, Other Insurer (Section 194 not applicable)	Nil	Self-attested copy of valid IRDAI registration certificate
Persons Covered under Section 393 (e.g. Mutual Funds, Govt.)	Nil	Self-attested copy of valid SEBI registration certificate
Category I and II Alternative Investment Fund	Nil	Self-attested copy of valid SEBI registration certificate
Submitting Order u/s 395 (lower or NIL certificate)	Rate provided in the Order	Lower/NIL withholding tax certificate

Tax Deduction Rates for Non-Resident Shareholders

For non-resident shareholders, including Foreign Institutional Investors (FII) and Foreign Portfolio Investors (FPI), the TDS rate is 20% plus applicable surcharge and cess, or the rate under the Double Taxation Avoidance Agreement (DTAA), whichever is lower. To avail DTAA benefits, shareholders must submit specific documents, including a self-attested copy of the PAN card, Tax Residency Certificate, and Form 41 filed electronically on the Indian Income Tax Portal.

Particulars of non-resident shareholders	Applicable rate	Documents required, if any
Non-resident shareholders (including FII/FPI)	20% (plus surcharge and cess) OR DTAA Rate*	PAN, Tax Residency Certificate, Form 41, Self-declaration
Submitting Order u/s 395 (lower or NIL certificate)	Rate provided in the Order	Lower/NIL withholding tax certificate

Compliance and Submission Deadlines

Shareholders must submit required forms and documents to claim exemption from tax deduction for the financial year 2026-27. The deadline for submission is August 12, 2026. Forms can be submitted via the Registrar and Transfer Agent’s website or email. Incomplete or unsigned forms received after this date will not be considered. The company will use a compliance check utility to determine the validity of PANs; invalid PANs will attract a higher TDS rate of 20% under Section 262 of the Income Tax Act.

Shareholders are also required to update their bank details to facilitate electronic remittance of dividends. Members holding shares in electronic form must furnish details to their depository participants, while those holding physical shares must provide details to the RTA, M/s. KFin Technologies Limited, along with a cancelled cheque.